Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

LungCancerCells_1200x675 — • Source: Shutterstock

Related Content

Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity

Oct 25 2016

Daiichi Sankyo Loses One, Gains One In Oncology

Jun 02 2016

$410m Ambit deal bolsters Daiichi Sankyo's oncology presence

Sep 29 2014

Related Companies

Daiichi Sankyo Co., Ltd.

AstraZeneca PLC

Roche Holding AG

Ambit Biosciences Corporation

Plexxikon, Inc.

Nektar Therapeutics

Additional Topics

Research & Development Companies Cancer BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window